CS Group, trading on the OTCQB market under the symbol CSDX, has appointed Shah Teelani & Associates, a Dubai-based audit firm registered with the Public Company Accounting Oversight Board (PCAOB), to consolidate and audit all 2025 financial statements for the group and its subsidiaries. This engagement covers CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH, reflecting the company's commitment to strengthening financial governance, regulatory compliance, and transparency as it pursues international expansion across the United States, GCC region, and Europe.
Management emphasized that appointing a PCAOB-registered audit firm represents a significant step in aligning the group's financial reporting structure with U.S. public company standards. This move aims to integrate its growing international operations under a unified reporting framework. The consolidated audit is expected to support enhanced financial clarity, streamline reporting processes, and strengthen investor confidence. The 2025 financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and the company's international distribution expansion.
Mohammad Essayed, Group Chief Financial Officer, stated that engaging Shah Teelani & Associates marks an important milestone in CS Group's evolution as a publicly traded company. As the company scales operations across multiple regions, establishing institutional-grade standards, transparency, and regulatory compliance in financial reporting is essential. This appointment strengthens the group's governance foundation and supports its long-term growth strategy. The company continues to focus on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.
For further information, please visit https://group-csd.com/. The appointment of a PCAOB auditor is particularly significant for companies trading on U.S. markets, as it ensures adherence to rigorous auditing standards mandated by the Sarbanes-Oxley Act. This development may enhance the company's credibility with institutional investors and facilitate future capital raising activities. For business and technology leaders, this move demonstrates how companies are adapting their financial infrastructures to support global operations while maintaining regulatory compliance across multiple jurisdictions.
